Exact Sciences recently announced its fourth quarter numbers, which included revenues between $34.9 million – $35.4 million and 82,000 completed Cologuard tests, an increase of 142 percent and 114 percent from last year, respectively.

“Cologuard is becoming a standard of care for 80 million Americans who should be screened for colon cancer,” Exact Sciences Chairman and CEO Kevin Conroy said in a statement. “Strong demand for Cologuard from both patients and health care providers reflects the great need for this innovative, easy-to-use colon cancer screening test.”

According to a release, for the entire 2016 year, Exact Sciences expects revenues between $90 million – $99.5 million, 244,000 completed Cologuard tests and expansion of its insurance coverage by 67 percent.

These are the preliminary results, as Exact Sciences said it will release its final 2016 financial results in February.